---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-040396"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:39:57.906916+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Instil Bio and ImmuneOnco outline global registrational strategy for SYN-2510 in NSCLC and TNBC

## Summary
- Global registrational strategy for SYN-2510/IMM2510 in front-line NSCLC and TNBC announced.
- Phase 1b/2 chemo combo in front-line NSCLC expected to start late 2024 in China; US IND submission for SYN-2510 targeted late 2024 for Phase 2 monotherapy in second-line NSCLC.
- Phase 1b/2 chemo combo in front-line TNBC expected to start early 2025 in China; potential global Phase 3 trials after proof-of-concept.
- US Phase 2 monotherapy trial in second-line NSCLC expected to support efficient enrollment of global Phase 3 studies.

## SEC filing metadata
- accession: 0001628280-24-040396
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/0001628280-24-040396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/til-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-040396
- JSON: https://secwatch.observer/filing/0001628280-24-040396.json
- Plain text: https://secwatch.observer/filing/0001628280-24-040396.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.